The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells

Biochemical and Biophysical Research Communications

Volumn 305, Issue 4, 2003, Pages 1099-1104

  Najafi, S Mahmoud A ^a,b,c   Li, Zheng ^a   Makino, Keishi ^a,b,c   Shao, Ruping ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEHRAN   (Iran)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

E1A; Expression; Induce; p21; Sp1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN SUBUNIT; VIRUS PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 0038242155     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00905-7     Document Type: Article

References (30)

1. Barbeau D., Charbonneau R., Whalen S.G., Bayley S.T., Branton P.E. Functional interactions within adenovirus E1A protein complexes. Oncogene. 9:1994;359-373.
2. Frisch S.M., Mymryk J.S. Adenovirus-5 E1A: paradox and paradigm. Nat. Rev./Mol. Cell. Biol. 3:2002;441-452.
3. Ben-Israel H., Kleinberger T. Adenovirus and cell cycle control. Front. Biosci. 7:2002;1369-1395.
4. Yan D.H., Shao R., Hung M.C. E1A cancer gene therapy. Panner C. Gene Therapy of Cancer. second ed. 2001;465-477 Academic Press, San Diego.
5. Mymryk J.S. Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene. 13:1996;1581-1589.
6. Hortobagyi G.N., Ueno N.T., Xia W., Zhang S., Wolf J.W., Putnam J.B., Weiden P.L., Willey J.S., Carey M., Warner D.L., Payne J.Y., Tucker S.D., Bartholomeusz C., Kilbourn R.G., De Jager R.L., Sneige N., Katz R.L., Daifuku R., Ibrahim N.K., Murray J.L., Theriault R.L., Valero V., Gershenson D.M., Bevers M.W., Huang L., Lopez-Berestein G., Hung M.C. Cationic liposome-mediated adenovirus type 5 E1A gene transfer to human breast and ovarian cancer cells and its biological effects: a phase I clinical trial. J. Clin. Oncol. 19:2001;3422-3433.
7. Villaret D., Glisson B., Kenady D., Hanna E., Carey M., Gleich L., Yoo G.H., Futran N., Hung M.C., Anklesaria P., Heald A.E. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 24:2002;661-669.
8. Yoo G.H., Hung M.C., Lopez-Berestein G., LaFollete S., Ensley J.F., Carey M., Baston E., Reynolds T.C., Murray J.L. Phase I of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clinc. Cancer Res. 7:2001;1237-1245.
9. Hung M.C., Hortobagyi G.N., Ueno N.T. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv. Exp. Med. Biol. 465:2000;171-180.
10. Chakravarti D., Ogryzko V., Kao H.Y., Nash A., Chen H., Nakatani Y., Evans R.M. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell. 96:1999;393-403.
11. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
12. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
13. Fattaey A.R., Harlow E., Helin K. Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol. Cell. Biol. 13:1993;7267-7277.
14. Flint J., Shenk T. Viral transactivating proteins. Annu. Rev. Genet. 31:1997;177-212.
15. Gallimore P.H., Turnell A.H. Adenovirus E1A: remodeling the host cell, a life or death experience. Oncogene. 20:2001;7824-7835.
16. Geisberg J.V., Chen J., Ricciardi R.P. Subregions of the adenovirus E1A transactivation domain target multiple components of the TFIID complex. Mol. Cell. Biol. 15:1995;6283-6290.
17. Schaeper U., Boyd J.M., Verma S., Uhlmann E., Subramanian T., Chinnadurai G. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc. Natl. Acad. Sci. USA. 92:1995;10467-10471.
18. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol. Cell. 9:2002;213-224.
19. Steinman R.A. Cell cycle regulators and hematopoiesis. Oncogene. 21:2002;3403-3413.
20. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
21. Kwong K.Y., Zou Y., Day C., Hung M.C. The suppression of colon cancer cell growth in nude mice by targeting β-catenin/TCF pathway. Oncogene. 21:2002;8340-8346.
22. Makino K., Yu D., Hung M.C. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene. 20:2001;2537-2543.
23. Shao R., Karunagaran D., Zhou B., Li K., Lo S., Deng J., Chiao P., Hung M.C. Inhibition of nuclear factor-B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem. 272:1997;32739-32742.
24. Lowe S.W., Ruley H.E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7:1993;535-545.
25. El-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., Hamilton S.R., Kinzler K.W., Vogelstein B. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:1995;2910-2919.
26. Vikhanskaya F., Erba E., D'Incalci M., Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res. 22:1994;1012-1017.
27. Negrini M., Sabbioni S., Haldar S., Possati L., Castagnoli A., Corallini A., Barbanti-Brodano G., Croce C.M. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res. 54:1994;1818-1824.
28. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:1995;935-944.
29. Park J.W., Jang M.A., Lee Y.H., Passaniti A., Kyu Kwon T. p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochim. Biophys. Res. Commun. 280:2001;244-248.
30. Sowa Y., Orita T., Hiranabe-Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann. N. Y. Acad. Sci. 886:1999;195-199.